Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Potent mixed delta/mu-opioid agonist identified by Glaxo Wellcome/Delta team

Sep. 4, 1998

Taisho discovers potent and selective CRF1 receptor antagonists with anxiolytic effects

Sep. 4, 1998

P&U, U of Maryland describe inhibitors of kynurenine aminotransferase

Sep. 4, 1998

Neuroprotective and antioxidant phenazines designed at Nippon Chemiphar

Sep. 4, 1998

Regeneron receives milestone payment from Sumitomo related to BDNF development

Sep. 4, 1998

Pfizer/Neurogen anxiolytic advances in clinical trials

Sep. 3, 1998

Pharmacological profile of new acetylcholinesterase inhibitor: T-82

Sep. 3, 1998

Therapeutics for cerebrovascular disorders in development at Nippon Chemiphar

Sep. 3, 1998

Compounds interacting with nicotinic receptors for cognitive and memory deficits

Sep. 2, 1998

Anticonvulsant benzamides prepared at SKB

Sep. 2, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...